CRL · 8-K · 20260805PR000115
AI Research Partnerships
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 31 · Surprise 42
Charles River joined Eli Lilly’s TuneLab AI/ML platform to provide non-clinical testing expertise for drug discovery and R&D modernization. It also collaborated with Arovella Therapeutics to provide in vitro Next Generation Sequencing services obtained through the PathoQuest acquisition. The company stated that the Arovella collaboration is intended to accelerate development of alternative cancer-treatment approaches, although no financial value or timeframe was disclosed.
Key facts
- Joined Eli Lilly's TuneLab AI/ML platform to provide non-clinical testing expertise. source